Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors : The Ohio State University Experience

To determine whether intraoperative high-dose-rate brachytherapy (IO-HDRBT) can be used to decrease the dose of external beam radiotherapy (EBRT) in the treatment of children with soft-tissue sarcomas and, thereby, reduce morbidity without compromising local control. From March 1992 through April 19...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of radiation oncology, biology, physics biology, physics, 2001-11, Vol.51 (3), p.729-735
Hauptverfasser: NAG, Subir, TIPPIN, Douglas, RUYMANN, Frederick B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 735
container_issue 3
container_start_page 729
container_title International journal of radiation oncology, biology, physics
container_volume 51
creator NAG, Subir
TIPPIN, Douglas
RUYMANN, Frederick B
description To determine whether intraoperative high-dose-rate brachytherapy (IO-HDRBT) can be used to decrease the dose of external beam radiotherapy (EBRT) in the treatment of children with soft-tissue sarcomas and, thereby, reduce morbidity without compromising local control. From March 1992 through April 1999, 13 pediatric patients were treated with IO-HDRBT, low-dose EBRT, chemotherapy, and radical surgery at 21 sites that were not amenable to intraoperative electron beam therapy. The IO-HDRBT dose at 5 mm depth was 10 to 12.5 Gy for close margins/microscopic disease at 14 sites and 12.5 to 15 Gy for gross disease at 7 sites. The treatment volumes ranged from 4 to 96 cm(3) (mean 27). The EBRT dose was limited to 27-30 Gy in most cases to minimize growth retardation and preserve normal organ function. After a median follow-up of 47 months (range 12-97), 11 patients were alive and without evidence of disease (overall survival rate 85%, 4-year actuarial survival rate 77%). Of the 2 who died, 1 had Stage III pulmonary blastoma with a sacral recurrence; the other had Stage IV undifferentiated synovial sarcoma with a pulmonary recurrence. One local failure occurred in a patient with gross residual disease after incomplete resection for Stage IV pulmonary blastoma. The local control rate was 95%, and morbidity was observed in 3 patients (23%). One patient developed impaired orbital growth with mild ptosis. Another patient required orthopedic pinning of her femoral subcapital epiphysis and construction of a neobladder secondary to urethral obstruction. The third patient required reimplantation of her autotransplanted kidney secondary to chronic urinary tract infection and ureteral reflux. IO-HDRBT allowed for reduction in EBRT without compromising local control or disease-free survival in children with soft-tissue sarcomas. Tumor beds inaccessible to electron beam methods could be satisfactorily encompassed with IO-HDRBT techniques.
doi_str_mv 10.1016/S0360-3016(01)01697-2
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72192878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72192878</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-d6bb9b7f1e36781ced68857d9b0341cfe6622b453f84978a42696e3a6e22c80f3</originalsourceid><addsrcrecordid>eNpFkE1P3DAQhi0EYreUnwDyhao9BPyROA63akULEhKHXaTeLMcZE6NNHGxvxf77etlVOc3IfuYd-0HogpJrSqi4WRIuSMFz-53QH7k0dcGO0JzKuil4Vf05RvP_yAx9ifGVEEJpXZ6iGaVVU0tazdH7w5iC9hMEndxfwL176YvORyjyAeA2aNNvU5-vpy22PuDc4xRApwHGhL3FE3ROp-AMTpvBh4hv8SozT73zeJl2Ic9jTg7RpS2-e8-bHIwGvqITq9cRzg_1DD3_ulst7ovHp98Pi5-PhSl5mYpOtG3T1pYCF_nFBjohZVV3TUt4SY0FIRhry4pbWeYv6ZKJRgDXAhgzklh-hr7tc6fg3zYQkxpcNLBe6xH8Jqqa0YbJWmaw2oMm-BgDWDUFN-iwVZSonXL1oVztfCpC1YdyxfLc5WHBph2g-5w6OM7A1QHQ0ei1DXo0Ln5yJSWEc8n_ASCNixE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72192878</pqid></control><display><type>article</type><title>Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors : The Ohio State University Experience</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>NAG, Subir ; TIPPIN, Douglas ; RUYMANN, Frederick B</creator><creatorcontrib>NAG, Subir ; TIPPIN, Douglas ; RUYMANN, Frederick B</creatorcontrib><description>To determine whether intraoperative high-dose-rate brachytherapy (IO-HDRBT) can be used to decrease the dose of external beam radiotherapy (EBRT) in the treatment of children with soft-tissue sarcomas and, thereby, reduce morbidity without compromising local control. From March 1992 through April 1999, 13 pediatric patients were treated with IO-HDRBT, low-dose EBRT, chemotherapy, and radical surgery at 21 sites that were not amenable to intraoperative electron beam therapy. The IO-HDRBT dose at 5 mm depth was 10 to 12.5 Gy for close margins/microscopic disease at 14 sites and 12.5 to 15 Gy for gross disease at 7 sites. The treatment volumes ranged from 4 to 96 cm(3) (mean 27). The EBRT dose was limited to 27-30 Gy in most cases to minimize growth retardation and preserve normal organ function. After a median follow-up of 47 months (range 12-97), 11 patients were alive and without evidence of disease (overall survival rate 85%, 4-year actuarial survival rate 77%). Of the 2 who died, 1 had Stage III pulmonary blastoma with a sacral recurrence; the other had Stage IV undifferentiated synovial sarcoma with a pulmonary recurrence. One local failure occurred in a patient with gross residual disease after incomplete resection for Stage IV pulmonary blastoma. The local control rate was 95%, and morbidity was observed in 3 patients (23%). One patient developed impaired orbital growth with mild ptosis. Another patient required orthopedic pinning of her femoral subcapital epiphysis and construction of a neobladder secondary to urethral obstruction. The third patient required reimplantation of her autotransplanted kidney secondary to chronic urinary tract infection and ureteral reflux. IO-HDRBT allowed for reduction in EBRT without compromising local control or disease-free survival in children with soft-tissue sarcomas. Tumor beds inaccessible to electron beam methods could be satisfactorily encompassed with IO-HDRBT techniques.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/S0360-3016(01)01697-2</identifier><identifier>PMID: 11597815</identifier><identifier>CODEN: IOBPD3</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Adolescent ; Biological and medical sciences ; Brachytherapy - methods ; Child ; Child, Preschool ; Combined Modality Therapy ; Dermatology ; Female ; Humans ; Intraoperative Period ; Male ; Medical sciences ; Radiation therapy and radiosensitizing agent ; Sarcoma - drug therapy ; Sarcoma - radiotherapy ; Sarcoma - surgery ; Survival Rate ; Treatment Outcome ; Treatment with physical agents ; Treatment. General aspects ; Tumors ; Tumors of the skin and soft tissue. Premalignant lesions</subject><ispartof>International journal of radiation oncology, biology, physics, 2001-11, Vol.51 (3), p.729-735</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-d6bb9b7f1e36781ced68857d9b0341cfe6622b453f84978a42696e3a6e22c80f3</citedby><cites>FETCH-LOGICAL-c434t-d6bb9b7f1e36781ced68857d9b0341cfe6622b453f84978a42696e3a6e22c80f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14100338$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11597815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NAG, Subir</creatorcontrib><creatorcontrib>TIPPIN, Douglas</creatorcontrib><creatorcontrib>RUYMANN, Frederick B</creatorcontrib><title>Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors : The Ohio State University Experience</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>To determine whether intraoperative high-dose-rate brachytherapy (IO-HDRBT) can be used to decrease the dose of external beam radiotherapy (EBRT) in the treatment of children with soft-tissue sarcomas and, thereby, reduce morbidity without compromising local control. From March 1992 through April 1999, 13 pediatric patients were treated with IO-HDRBT, low-dose EBRT, chemotherapy, and radical surgery at 21 sites that were not amenable to intraoperative electron beam therapy. The IO-HDRBT dose at 5 mm depth was 10 to 12.5 Gy for close margins/microscopic disease at 14 sites and 12.5 to 15 Gy for gross disease at 7 sites. The treatment volumes ranged from 4 to 96 cm(3) (mean 27). The EBRT dose was limited to 27-30 Gy in most cases to minimize growth retardation and preserve normal organ function. After a median follow-up of 47 months (range 12-97), 11 patients were alive and without evidence of disease (overall survival rate 85%, 4-year actuarial survival rate 77%). Of the 2 who died, 1 had Stage III pulmonary blastoma with a sacral recurrence; the other had Stage IV undifferentiated synovial sarcoma with a pulmonary recurrence. One local failure occurred in a patient with gross residual disease after incomplete resection for Stage IV pulmonary blastoma. The local control rate was 95%, and morbidity was observed in 3 patients (23%). One patient developed impaired orbital growth with mild ptosis. Another patient required orthopedic pinning of her femoral subcapital epiphysis and construction of a neobladder secondary to urethral obstruction. The third patient required reimplantation of her autotransplanted kidney secondary to chronic urinary tract infection and ureteral reflux. IO-HDRBT allowed for reduction in EBRT without compromising local control or disease-free survival in children with soft-tissue sarcomas. Tumor beds inaccessible to electron beam methods could be satisfactorily encompassed with IO-HDRBT techniques.</description><subject>Adolescent</subject><subject>Biological and medical sciences</subject><subject>Brachytherapy - methods</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Combined Modality Therapy</subject><subject>Dermatology</subject><subject>Female</subject><subject>Humans</subject><subject>Intraoperative Period</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Radiation therapy and radiosensitizing agent</subject><subject>Sarcoma - drug therapy</subject><subject>Sarcoma - radiotherapy</subject><subject>Sarcoma - surgery</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Treatment with physical agents</subject><subject>Treatment. General aspects</subject><subject>Tumors</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1P3DAQhi0EYreUnwDyhao9BPyROA63akULEhKHXaTeLMcZE6NNHGxvxf77etlVOc3IfuYd-0HogpJrSqi4WRIuSMFz-53QH7k0dcGO0JzKuil4Vf05RvP_yAx9ifGVEEJpXZ6iGaVVU0tazdH7w5iC9hMEndxfwL176YvORyjyAeA2aNNvU5-vpy22PuDc4xRApwHGhL3FE3ROp-AMTpvBh4hv8SozT73zeJl2Ic9jTg7RpS2-e8-bHIwGvqITq9cRzg_1DD3_ulst7ovHp98Pi5-PhSl5mYpOtG3T1pYCF_nFBjohZVV3TUt4SY0FIRhry4pbWeYv6ZKJRgDXAhgzklh-hr7tc6fg3zYQkxpcNLBe6xH8Jqqa0YbJWmaw2oMm-BgDWDUFN-iwVZSonXL1oVztfCpC1YdyxfLc5WHBph2g-5w6OM7A1QHQ0ei1DXo0Ln5yJSWEc8n_ASCNixE</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>NAG, Subir</creator><creator>TIPPIN, Douglas</creator><creator>RUYMANN, Frederick B</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011101</creationdate><title>Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors : The Ohio State University Experience</title><author>NAG, Subir ; TIPPIN, Douglas ; RUYMANN, Frederick B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-d6bb9b7f1e36781ced68857d9b0341cfe6622b453f84978a42696e3a6e22c80f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Biological and medical sciences</topic><topic>Brachytherapy - methods</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Combined Modality Therapy</topic><topic>Dermatology</topic><topic>Female</topic><topic>Humans</topic><topic>Intraoperative Period</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Radiation therapy and radiosensitizing agent</topic><topic>Sarcoma - drug therapy</topic><topic>Sarcoma - radiotherapy</topic><topic>Sarcoma - surgery</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Treatment with physical agents</topic><topic>Treatment. General aspects</topic><topic>Tumors</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NAG, Subir</creatorcontrib><creatorcontrib>TIPPIN, Douglas</creatorcontrib><creatorcontrib>RUYMANN, Frederick B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NAG, Subir</au><au>TIPPIN, Douglas</au><au>RUYMANN, Frederick B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors : The Ohio State University Experience</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2001-11-01</date><risdate>2001</risdate><volume>51</volume><issue>3</issue><spage>729</spage><epage>735</epage><pages>729-735</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><coden>IOBPD3</coden><abstract>To determine whether intraoperative high-dose-rate brachytherapy (IO-HDRBT) can be used to decrease the dose of external beam radiotherapy (EBRT) in the treatment of children with soft-tissue sarcomas and, thereby, reduce morbidity without compromising local control. From March 1992 through April 1999, 13 pediatric patients were treated with IO-HDRBT, low-dose EBRT, chemotherapy, and radical surgery at 21 sites that were not amenable to intraoperative electron beam therapy. The IO-HDRBT dose at 5 mm depth was 10 to 12.5 Gy for close margins/microscopic disease at 14 sites and 12.5 to 15 Gy for gross disease at 7 sites. The treatment volumes ranged from 4 to 96 cm(3) (mean 27). The EBRT dose was limited to 27-30 Gy in most cases to minimize growth retardation and preserve normal organ function. After a median follow-up of 47 months (range 12-97), 11 patients were alive and without evidence of disease (overall survival rate 85%, 4-year actuarial survival rate 77%). Of the 2 who died, 1 had Stage III pulmonary blastoma with a sacral recurrence; the other had Stage IV undifferentiated synovial sarcoma with a pulmonary recurrence. One local failure occurred in a patient with gross residual disease after incomplete resection for Stage IV pulmonary blastoma. The local control rate was 95%, and morbidity was observed in 3 patients (23%). One patient developed impaired orbital growth with mild ptosis. Another patient required orthopedic pinning of her femoral subcapital epiphysis and construction of a neobladder secondary to urethral obstruction. The third patient required reimplantation of her autotransplanted kidney secondary to chronic urinary tract infection and ureteral reflux. IO-HDRBT allowed for reduction in EBRT without compromising local control or disease-free survival in children with soft-tissue sarcomas. Tumor beds inaccessible to electron beam methods could be satisfactorily encompassed with IO-HDRBT techniques.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>11597815</pmid><doi>10.1016/S0360-3016(01)01697-2</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0360-3016
ispartof International journal of radiation oncology, biology, physics, 2001-11, Vol.51 (3), p.729-735
issn 0360-3016
1879-355X
language eng
recordid cdi_proquest_miscellaneous_72192878
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Adolescent
Biological and medical sciences
Brachytherapy - methods
Child
Child, Preschool
Combined Modality Therapy
Dermatology
Female
Humans
Intraoperative Period
Male
Medical sciences
Radiation therapy and radiosensitizing agent
Sarcoma - drug therapy
Sarcoma - radiotherapy
Sarcoma - surgery
Survival Rate
Treatment Outcome
Treatment with physical agents
Treatment. General aspects
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
title Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors : The Ohio State University Experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T17%3A43%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intraoperative%20high-dose-rate%20brachytherapy%20for%20the%20treatment%20of%20pediatric%20tumors%20:%20The%20Ohio%20State%20University%20Experience&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=NAG,%20Subir&rft.date=2001-11-01&rft.volume=51&rft.issue=3&rft.spage=729&rft.epage=735&rft.pages=729-735&rft.issn=0360-3016&rft.eissn=1879-355X&rft.coden=IOBPD3&rft_id=info:doi/10.1016/S0360-3016(01)01697-2&rft_dat=%3Cproquest_cross%3E72192878%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72192878&rft_id=info:pmid/11597815&rfr_iscdi=true